Nyrada Quarterly Activities Report and Appendix 4C

Cholesterol-Lowering Program:
• Significant work completed during the quarter progressing and understanding the mechanisms underlying Nyrada’s cholesterol-lowering program drug candidate NYX-1492.
• Notwithstanding, NYX-1492 will not be advanced further as a treatment for high cholesterol.
• Alternative PCSK9 inhibitor candidates, structurally differentiated from NYX-1492, will be evaluated.

Brain Injury Program:
• NYR-BI03, a close analogue of NYR-BI02 with an improved safety profile, was determined as Nyrada’s new lead brain injury drug candidate.
• NYR-BI03 will be tested in the Walter Reed Army Institute of Research (WRAIR) Traumatic Brain Injury (TBI) efficacy study, and separately in a Contract Research Organisation (CRO) stroke model study.
• A paper published in the journal Translational Stroke Research validated Nyrada’s TRPC channel drug target for secondary brain injury neuroprotection.
• Nyrada to present on its brain injury neuroprotection drug program at a major US Department of Defense health conference.

Corporate and Financial:
• Cash balance of AU$3.7M at end June 2023, material Research and Development (R&D) tax incentive program refund expected, and operating cost review underway.